Cargando…
Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?
The lowering of high blood pressure is supposed to protect target organs from hypertensive damage. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial was designed to compare the cardioprotective properties of three antihypertensives from different classes (lisinopril, am...
Autores principales: | Gavras, Irene, Gavras, Haralambos |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64825/ https://www.ncbi.nlm.nih.gov/pubmed/11806808 http://dx.doi.org/10.1186/cvm-2-6-257 |
Ejemplares similares
-
Comments on ALLHAT and doxazosin
por: Krakoff, Lawrence R
Publicado: (2001) -
Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone
por: Piller, Linda B, et al.
Publicado: (2002) -
Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT
por: Shahu, Andi, et al.
Publicado: (2019) -
Prevention of Heart Failure in Hypertension—Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study
por: Johnson, Kyle, et al.
Publicado: (2019) -
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins
por: Hooper, Philip L
Publicado: (2001)